scholarly journals Impact of supplementation with vitamins B 6 , B 12 , and/or folic acid on the reduction of homocysteine levels in patients with mild cognitive impairment: A systematic review

IUBMB Life ◽  
2021 ◽  
Author(s):  
Gloria Olaso‐Gonzalez ◽  
Marco Inzitari ◽  
Giuseppe Bellelli ◽  
Alessandro Morandi ◽  
Núria Barcons ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cognitive Impairment ◽  
Folic Acid ◽  
Mild Cognitive Impairment

scholarly journals Folic acid supplementation improves cognitive function: a systematic review

2020 ◽  
Author(s):  
I Putu Eka Widyadharma ◽  
Eric Hartono Tedyanto ◽  
Anak Agung Ayu Putri Laksmidewi ◽  
I Made Oka Adnyana ◽  
Dewa Putu Gede Purwa Samatra
Keyword(s):  
Systematic Review ◽  
Cognitive Impairment ◽  
Folic Acid ◽  
Mild Cognitive Impairment ◽  
Cognitive Function ◽  
Randomized Controlled Trials ◽  
Folic Acid Supplementation ◽  
Controlled Trials ◽  
Acid Supplementation ◽  
Randomized Controlled

The most common type of dementia is Alzheimer’s disease (AD). AD is characterized by loss of memory and cognitive impairment. In epidemiological studies, low folate could disturb vitamin B12 absorption, which leads to the inflammatory process, and it explains the association between both vitamins and AD. Authors did a systematic search through PubMed and Embase according to the PRISMA protocol. Authors included studies published in the last 5 years (from 2015 to June 2020). Authors assess the quality of studies using JADAD Scale for randomized-controlled trials. Authors found 426 journals in their search strategy. In the end, 2 studies met the eligibility criteria and were included in this review. These two randomized controlled trials revealed that folic acid improved cognitive function in AD (p<0.05) and mild cognitive impairment (p=0.028). In this systematic review, authors found that daily folic acid supplements could improve cognitive function in patients with AD and mild cognitive impairment. The exact mechanism is unknown, but it is believed that folic acid supplementation improves cognitive function by reducing the levels of peripheral inflammatory cytokines. Daily oral folic acid supplemental (400 µg and 1.2 mg) for 6-12 months improves cognitive function in AD and mild cognitive Impairment.

Incidence of mild cognitive impairment - a systematic review

2011 ◽  
Vol 38 (S 01) ◽  
Author(s):  
T Luck ◽  
M Luppa ◽  
S Briel ◽  
SG Riedel-Heller
Keyword(s):  
Systematic Review ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment

A Systematic Review of Amnestic and Non-Amnestic Mild Cognitive Impairment Induced by Anticholinergic, Antihistamine, GABAergic and Opioid Drugs

Drugs & Aging ◽  
2012 ◽  
Vol 29 (8) ◽  
pp. 639-658 ◽  
Author(s):  
Cara Tannenbaum ◽  
Amélie Paquette ◽  
Sarah Hilmer ◽  
Jayna Holroyd-Leduc ◽  
Ryan Carnahan
Keyword(s):  
Systematic Review ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Amnestic Mild Cognitive Impairment ◽  
Opioid Drugs

Prevalence of mild cognitive impairment in patients with hypertension: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Jiawei Qin ◽  
Zexiang He ◽  
Lijian Wu ◽  
Wanting Wang ◽  
Qiuxiang Lin ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Meta Analysis

scholarly journals Prevalence of Mild Cognitive Impairment in Latin America and the Caribbean: A Systematic Review

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 897-898
Author(s):  
Fabiana Ribeiro ◽  
Ana Carolina Teixeira-Santos ◽  
Anja Leist
Keyword(s):  
Systematic Review ◽  
Latin America ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
English Language ◽  
Prevalence Data ◽  
Gender And Education ◽  
Precise Diagnosis ◽  
Normal Ageing ◽  
The Caribbean

Abstract Background. The population of Latin America and the Caribbean (LAC) is ageing rapidly, presenting the highest prevalence rates of dementia in the world. In this context, mild cognitive impairment (MCI) is an intermediate condition between normal ageing and dementia. However, very few studies verified the prevalence of MCI in LAC countries; earlier global systematic reviews only considered prevalence reports published in English language. Method. We conducted a systematic review to evaluate the prevalence of MCI in LAC countries and to explore the factors associated with MCI (i.e., age, gender, and education). A database search was conducted in February 2020 using PubMed, Web of Science, Scopus, Lilacs, SciELO, and EMBASE, for population-or community-based studies with MCI data for countries in LAC, published in English, Spanish, or Portuguese language. From k=2,168 identified and k=1,684 screened studies, only articles were selected that included subjects with a precise diagnosis of MCI. The studies were qualitatively assessed using the JBI critical appraisal checklist for studies reporting prevalence data tool. Results. A total of nine studies met the criteria, published between 2007 and 2019, including a total of 17,812 participants in nine countries Brazil, Mexico, Argentina, Colombia, Peru, Cuba, Dominican Republic, Venezuela, and Costa Rica. Estimates for MCI prevalence ranged from 1.2% to 34%, with most estimates between 1.2% and 6.45%. Estimates differed by age group, gender, and educational level. Discussion. This is the first systematic review of the prevalence of MCI in LAC countries, considering only high-quality studies adopting rigorous diagnostic criteria.

scholarly journals Repetition Priming in Individuals with Amnestic Mild Cognitive Impairment and Alzheimer’s Dementia: a Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Liselotte De Wit ◽  
Vitoria Piai ◽  
Pilar Thangwaritorn ◽  
Brynn Johnson ◽  
Deirdre O’Shea ◽  
...  
Keyword(s):  
Systematic Review ◽  
Older Adults ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Repetition Priming ◽  
Meta Analysis ◽  
Healthy Older Adults ◽  
Amnestic Mci ◽  
Standard Mean Difference ◽  
Priming Paradigm

AbstractThe literature on repetition priming in Alzheimer’s disease (AD) is inconsistent, with some findings supporting spared priming while others do not. Several factors may explain these inconsistencies, including AD severity (e.g., dementia vs. Mild Cognitive Impairment; MCI) and priming paradigm-related characteristics. This systematic review and meta-analysis provides a quantitative summary of repetition priming in AD. We examined the between-group standard mean difference comparing repetition priming in AD dementia or amnestic MCI (aMCI; presumably due to AD) to controls. Thirty-two studies were selected, including 590 individuals with AD dementia, 267 individuals with amnestic MCI, and 703 controls. Our results indicated that both individuals with aMCI and AD dementia perform worse on repetition priming tasks than cognitively older adults. Paradigm-related moderators suggested that the effect size between studies comparing the combined aMCI or AD dementia group to cognitively healthy older adults was the highest for paradigms that required participants to produce, rather than identify, primes during the test phase. Our results further suggested that priming in AD is impaired for both conceptual and perceptual priming tasks. Lastly, while our results suggested that priming in AD is impaired for priming tasks that require deep processing, we were unable to draw firm conclusions about whether priming is less impaired in aMCI or AD dementia for paradigms that require shallow processing.

Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial

2021 ◽  
pp. 1-13
Author(s):  
Dong Bai ◽  
Junting Fan ◽  
Mengyue Li ◽  
Cuixia Dong ◽  
Yiming Gao ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Folic Acid ◽  
Mild Cognitive Impairment ◽  
Cognitive Function ◽  
Digit Span ◽  
Controlled Trial ◽  
Amyloid Β ◽  
Amyloid Β Peptide ◽  
Double Blind ◽  
Full Scale Intelligence Quotient

Background: The neuroprotective benefits of combined folic acid and docosahexaenoic acid (DHA) on cognitive function in mild cognitive impairment (MCI) patients are suggested but unconfirmed. Objective: To explore the effects of 6-month folic acid + DHA on cognitive function in patients with MCI. Methods: Our randomized controlled trial (trial number ChiCTR-IOR-16008351) was conducted in Tianjin, China. We divided 160 MCI patients aged >  60 years into four regimen groups randomly: folic acid (0.8 mg/day) + DHA (800 mg/day), folic acid (0.8 mg/day), DHA (800 mg/day), and placebo, for 6 months. Cognitive function and blood amyloid-β peptide (Aβ) biomarker levels were measured at baseline and 6 months. Cognitive function was also measured at 12 months. Results: A total of 138 patients completed this trial. Folic acid improved the full-scale intelligence quotient (FSIQ), arithmetic, and picture complement scores; DHA improved the FSIQ, information, arithmetic, and digit span scores; folic acid + DHA improved the arithmetic (difference 1.67, 95% CI 1.02 to 2.31) and digital span (1.33, 0.24 to 2.43) scores compared to placebo. At 12 months, all scores declined in the intervention groups. Folic acid and folic acid + DHA increased blood folate (folic acid + DHA: 7.70, 3.81 to 11.59) and S-adenosylmethionine (23.93, 1.86 to 46.00) levels and reduced homocysteine levels (–6.51, –10.57 to –2.45) compared to placebo. DHA lower the Aβ40 levels (–40.57, –79.79 to –1.35) compared to placebo (p <  0.05), and folic acid + DHA reduced the Aβ42 (–95.59, –150.76 to –40.43) and Aβ40 levels (–45.75, –84.67 to –6.84) more than DHA (p <  0.05). Conclusion: Folic acid and DHA improve cognitive function and reduce blood Aβ production in MCI patients. Combination therapy may be more beneficial in reducing blood Aβ-related biomarkers.

Sign in / Sign up

Export Citation Format

Share Document